The Efficacy of an Oral Formulation of , , and as an Add-on Therapy for Mild-to-moderate Childhood Asthma: A Randomized Placebo-Controlled Clinical Trial.

Objective: We aimed to evaluate the efficacy of an oral combined tablet of (Anti-Asthma) as an add-on therapy for the relief of the severity of symptoms in mild-to-moderate childhood asthma.

Methods: This randomized placebo-controlled clinical trial was performed on 60 children and adolescents with chronic mild-to-moderate childhood asthma. Patients were randomly divided into cases who received Anti-Asthma oral combined tablets 2 tablets twice dailt for 1 month and controls, received placebo tablets identically the same to Anti-Asthma (2 tablets, twice daily, for 1 month) as add-ons to their standard therapy according to the guideline.

Evaluation of paraoxonase activity in children with nephrotic syndrome.

Background: It has been proposed that reactive oxygen species (ROS) is involved in the pathogenesis of various diseases. Paraoxonase, a high-density lipoprotein associated enzyme, prevents low-density lipoproteins from oxidation.

Objectives: The aim of the present study was to investigate the serum activities of paraoxonase-1 (PON-1), and aryleterase (ARE) as well as total antioxidant capacity (TAC) in children with nephrotic syndrome in acute and remission phase.